This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Moleculera Labs, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Oklahoma. Active years: 2006-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
2 out of 3,696 
2 out of 576 
Years Active: 2006-2019
Title: Craig David Shimasaki: Innovator in Pediatric Neuropsychiatric Diagnostics.
Introduction
Craig David Shimasaki is a notable inventor based in Edmond, OK (US). He has made significant contributions to the field of pediatric neuropsychiatric disorders, particularly through his innovative diagnostic methods. With a total of 3 patents, Shimasaki's work is paving the way for better understanding and treatment of conditions such as pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS).
Latest Patents
Shimasaki's latest patents focus on a diagnostic method for PANS and PANDAS. This invention provides a panel of at least five clinical analyses or tests using serum samples to determine the risk of these disorders in individuals. The tests include enzyme-linked immunosorbent assays (ELISAs) to measure antibody titers against various neuronal antigens present in the brain. These antigens include lysoganglioside, tubulin, dopamine receptors, and serotonin receptors. The method requires measuring antibody titers against at least four of these antigens, with a final assay quantifying calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results are combined using an algorithm to assess the appropriateness of a PANS or PANDAS diagnosis, which can guide treatment options.
Career Highlights
Throughout his career, Shimasaki has worked with reputable organizations, including the University of Oklahoma and Moleculera Labs, Inc. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to advancements in pediatric neuropsychiatric diagnostics.
Collaborations
Some of Shimasaki's notable coworkers include Phina Madeleine Cunningham and Susan E Swedo. Their collaborative efforts have further enhanced the research and development of diagnostic methods for pediatric neuropsychiatric disorders.
Conclusion
Craig David Shimasaki's innovative work in the field of pediatric neuropsychiatric diagnostics is making a significant impact on the understanding and treatment of PANS and PANDAS. His contributions are essential for advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile